MedTrace Logo

A Study of ALXN1830 in Healthy Adult Participants

NCT04730804 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 34

Last updated 2024-09-19

Study results available
· View outcomes & findings →

Summary

This trial will study the effects of single and multiple doses of ALXN1830 in healthy adult participants.

Conditions

  • Healthy

Interventions

DRUG

ALXN1830

ALXN1830 will be administered as SC infusion(s).

DRUG

Placebo

Placebo will be administered as SC infusion(s).

Sponsors & Collaborators

  • Syneos Health

    collaborator OTHER

  • Alexion Pharmaceuticals, Inc.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-03-17
Primary Completion
2021-12-14
Completion
2022-01-04
FDA Drug
Yes

Countries

  • New Zealand

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04730804 on ClinicalTrials.gov